Paricalcitol Generics Suppliers & Bulk Manufacturers

Available Forms: Capsules and Injection

Available Strengths: Capsules:1mcg, 2mcg, 4 mcg & Injection: 2mcg/mL , 5mcg/mL

Reference Brands: Zemplar®(US &EU)

Category: Nephrology

Paricalcitol (Zemplar®) is a selective vitamin D receptor activator used to manage secondary hyperparathyroidism in CKD patients, available as oral capsules and IV injection. Approved in both the EU and US, it offers targeted PTH control with a lower risk of hypercalcemia and hyperphosphatemia. Suitable for hospital tenders, licensing, and distribution in the global renal care market. Paricalcitol Generics is available in Capsules and Injection and strengths such as Capsules:1mcg, 2mcg, 4 mcg & Injection: 2mcg/mL , 5mcg/mL. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Paricalcitol Generics is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Paricalcitol Generics can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Paricalcitol, marketed as Zemplar®, is a selective vitamin D receptor activator used to treat secondary hyperparathyroidism in patients with chronic kidney disease (CKD), both on dialysis (stage 5) and in pre-dialysis stages (3–4). It effectively lowers parathyroid hormone (PTH) levels while minimizing the risk of hypercalcemia and hyperphosphatemia. Available as oral capsules (1 mcg, 2 mcg, 4 mcg) and IV injection (2 mcg/mL, 5 mcg/mL), Paricalcitol is approved in both the US (FDA) and EU (EMA). It is a key therapeutic in nephrology and an excellent B2B opportunity for licensing, distribution, and hospital-based partnerships in regulated markets.